Private Equity Scale Hits New High, Fund Purchase Restrictions Loosened and Innovative Drug ETFs Expand - New Landscape of China's Asset Management Industry
Keywords
Private Equity; Scale High; Purchase Restrictions Loosened; Innovative Drug Fund; Active ETF; Asset Management
Introduction
Since 2024, China's asset management industry has shown multiple positive signals, with market vitality and structural optimization advancing simultaneously. According to the latest industry data, the private equity management scale has climbed to 23.66 trillion yuan, setting a new historical high. Meanwhile, many public funds with excellent past performance have announced the resumption of large-scale subscriptions, marking a relaxation of the previous situation where funds had voluntarily restricted purchases due to excessive scale. In addition, the total scale of innovative drug-themed funds has exceeded 150 billion yuan, showing the strong recovery momentum of the pharmaceutical sector driven by both policy and market demand. More notably, active ETF pilot programs have steadily expanded, providing investors with more diversified tool choices. These changes not only reflect the gradual recovery of market confidence but also reveal that the asset management industry is entering a new stage that focuses more on quality and innovation. This article will conduct an in-depth analysis from the above four dimensions, exploring the driving factors, industry impacts and future trends behind them.
1. Private Equity Scale Hits New High: Driving Factors and Industry Impact
The private equity scale breaking through 23.66 trillion yuan not only refreshes historical records but also marks the formal entry of China's private equity industry into a "golden age." From the perspective of driving factors, there are three main aspects: first, the continuous growth of household wealth management needs, especially against the background of declining interest rates and decreasing returns on traditional wealth management products, high-net-worth clients' willingness to allocate to private equity has significantly increased; second, the structural trend of the A-share market continues to unfold, with various private equity products such as quantitative strategies, long-only and bond strategies showing differentiated performance, and leading institutions attracting large capital inflows with their stable absolute return capabilities; third, the policy environment has been further optimized, such as the implementation of the "Regulations on the Supervision and Administration of Private Equity Investment Funds" which has raised industry access thresholds, enhanced compliance, and boosted investor confidence.
In terms of impact, the new high in scale means that the private equity industry's voice in the capital market has been further enhanced. On the one hand, as important long-term investors, the investment behavior of private equity institutions has a profound impact on market pricing efficiency, corporate governance and industrial upgrading; on the other hand, the expansion of scale also brings the hidden worry of "curse of scale"—some products with limited strategy capacity face challenges such as declining excess returns and increased liquidity management difficulties. In the future, the industry will shift from "scale expansion" to "quality improvement", and leading private equity institutions need to continuously improve in investment research capabilities, risk control and customer service to maintain their competitive edge.
2. Loosening of Purchase Restrictions on High-Performance Funds: Positive Signal or Risk Warning?
Recently, many top-performing public funds announced the resumption of large-scale subscriptions, which had previously voluntarily restricted purchases due to excessive scale or market overheating. This change is interpreted by the market as an interweaving of multiple signals. First, the loosening of purchase restrictions often means that fund managers recognize the current market valuation, believe that valuations have become attractive, and are willing to absorb more funds to capture long-term opportunities. For example, some high-performance funds focusing on dividends, technology and other sectors have returned to reasonable valuation ranges after adjustments, and fund managers are opening subscriptions to increase revenue flexibility. Secondly, the loosening of purchase restrictions may also reflect fund companies' re-planning of scale growth. Against the background of intensified industry competition, leading fund companies are more inclined to attract incremental funds through "star funds" to consolidate market share.
However, this signal is not entirely positive. Investors need to guard against the reactivation of "buying high and selling low" emotions. Historically, the opening of large-scale fund subscriptions often coincides with market highs at certain stages, and some funds that enter at high levels may face short-term volatility risks. In addition, the issue of fund managers' management boundaries cannot be ignored. If scale growth exceeds their capability circle, excess returns will inevitably be diluted. Therefore, the loosening of purchase restrictions is both an active embrace of market opportunities and a test of fund managers' management capabilities. When choosing such funds, investors should focus more on whether the fund manager's investment logic is stable, whether the strategy capacity matches, and whether the fund company's overall investment research system can support scale expansion.
3. Innovative Drug-Themed Funds Exceed 150 Billion Yuan: Pharmaceutical Sector Recovery and Long-Term Value
The total scale of innovative drug-themed funds exceeding 150 billion yuan reflects the value return of the pharmaceutical industry after deep adjustments. From a fundamental perspective, the driving factors in the innovative drug field are clear and strong: on the policy side, the National Healthcare Security Administration continues to promote the inclusion of innovative drugs in the medical insurance catalog, accelerate the approval process, and provide a clear commercialization path for innovative drug companies; on the technology side, China has already joined the world's first echelon in cutting-edge fields such as ADC (antibody-drug conjugates), bispecific antibodies, and cell therapy, with significant achievements of many domestic pharmaceutical companies going global; on the demand side, deepening population aging and rising prevalence of chronic diseases provide broad market space for innovative drugs.
Notably, the rapid growth in the scale of innovative drug-themed funds also reflects investors' long-term confidence in this sector. Compared with traditional generic drugs and medical devices, innovative drugs are characterized by high barriers, high risks and high returns, and their investment logic focuses more on the value evaluation of the R&D pipeline and the management of clinical progress uncertainty. Currently, institutional investors generally optimistic about the long-term narrative of Chinese innovative drugs "going global", believing that domestic companies will occupy a more important share in the global market. Therefore, innovative drug-themed funds are not only an important细分方向 for pharmaceutical investment but also a micro-reflection of China's transition from a "big pharmaceutical country" to a "strong pharmaceutical country".
But investors also need to remain rational. The innovative drug industry is highly volatile, with risks such as R&D failures, policy adjustments, and intensified market competition always existing. After the scale exceeds 150 billion yuan, the strategy capacity and liquidity management of related funds face challenges, especially when market sentiment turns pessimistic, concentrated redemptions may intensify net value fluctuations. It is recommended that investors participate through fixed investment or diversified allocation to avoid the risk of betting on a single细分领域.
4. Steady Expansion of Active ETF Pilot Programs: Product Innovation and Investor Choices
Active ETF (Exchange Traded Fund) pilot programs have steadily expanded, becoming one of the most noteworthy product innovations in the asset management field in 2024. Traditional passive ETFs mainly track indices, while active ETFs give fund managers greater freedom in stock selection, striving for excess returns through active management within the index framework. This product form combines the transparency and trading convenience of ETFs with the flexibility of actively managed funds, and is growing rapidly worldwide.
China's active ETF pilot program began in early 2024, and so far more than ten fund companies have been approved to issue related products, covering multiple themes such as consumption, technology, medicine, and dividends. The steady expansion behind it is the joint effect of three factors: first, regulators encourage product innovation, promoting the fund industry to transition from "homogeneous competition" to "differentiated development"; second, investors' dual demands for trading efficiency and excess returns are increasingly strong, and active ETFs just balance the two; third, the improvement of fund managers' capabilities in the integration of quantitative and fundamental analysis provides technical support for the operation of active ETFs.
For investors, the emergence of active ETFs means more choices. Traditional active funds have disadvantages such as low subscription/redemption efficiency and delayed information disclosure, while active ETFs can be traded in real-time in the secondary market and disclose positions daily, with higher transparency. However, it should be noted that the management fee rate of active ETFs is usually higher than that of passive ETFs, and the active management ability of fund managers is still the core variable determining returns. Therefore, when choosing active ETFs, investors should focus on the fund manager's historical performance, investment framework, and the fund company's investment research support.
Looking ahead, the expansion of active ETFs will accelerate the evolution of China's ETF market from "instrumentalization" to "stratification". As the pilot scope expands to more industry themes and even extends to cross-border and commodity fields, active ETFs are expected to become an important tool for individual and institutional investors' asset allocation.
Conclusion
In 2024, China's asset management industry started strongly, with private equity scale hitting a new high, high-performance funds loosening purchase restrictions, innovative drug-themed funds breaking through the 100 billion mark, and active ETF pilot programs expanding. These four signals together outline a market picture full of vitality and structural optimization. The leap in private equity scale highlights the trend of household asset allocation shifting to the equity market, the loosening of purchase restrictions on high-performance funds tests the management boundaries of managers and investor rationality, the high growth of innovative drug funds reflects the certain value of long-term tracks, and the expansion of active ETFs shows the innovation momentum of the product supply side.
Looking ahead, the industry faces both challenges and opportunities. For asset management institutions, whether they can maintain absolute return capabilities while growing in scale is key to maintaining investor trust; for investors, making rational choices in a diversified product matrix and avoiding buying high and selling low will become an important ability to survive the cycle. It can be predicted that China's asset management industry is transitioning from "quantitative expansion" to "qualitative leap", and institutions that continue to deepen in investment research depth, risk control systems, and customer service will occupy the commanding heights in the new round of competition. The continuous growth of emerging products such as active ETFs and innovative drug-themed funds will also inject new vitality into the capital market and help high-quality economic development.
